News Sentiment

TARS sentiment intelligence

Tarsus Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 59.85 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.9% over one week, -5.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive -5.2% over four weeks
Fair value 34.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 25
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
TradingView 5
Moomoo 4
simplywall.st 4
VisionMonday.com 2
Orange County Business Journal 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 13
Deals and strategy 9
Analyst action 3
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Simply Wall Street Direct company coverage

Is Tarsus Pharmaceuticals (TARS) Undervalued Following Culper’s Short Report?

Following a short report from Culper Research, Tarsus Pharmaceuticals (TARS) saw its stock price drop, but it now trades at a significant discount to analyst targets and intrinsic value estimates. The report alleged illegal Medicare copay practices and overstated 2026 profit proj

Tone
Positive 63/100
Event
Earnings
Published
06 Jul 2026 23:41
Source
Simply Wall Street
Moomoo Direct company coverage

Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100

Mizuho Securities has reiterated its Buy rating on Tarsus Pharmaceuticals (TARS.US) and maintained a price target of $100. This continued positive outlook suggests the firm sees strong potential in the company's future performance. Investors will likely be interested in the ratio

Tone
Positive 70/100
Event
Analyst action
Published
06 Jul 2026 21:40
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS

The article discusses the price to sales forward metric for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of financial information available for the company.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 20:10
Source
TradingView